Looking at the individual targets instead of just the headline number, the verified analyst price targets for COYA include $12 from Roth MKM, $18 from H.C. Wainwright, $17 from Lake Street, $16 from BTIG, $14 from Chardan Capital, and $15 from D. Boral Capital. These six targets produce an arithmetic mean of approximately $15.3, which rounds to a clean central target of $15. The low-to-high range spans $12 to $18, a spread of roughly 50%.
That dispersion matters. A clinical-stage company with no approved therapy derives most of its value from the probability that its lead program succeeds, so analysts assign different probabilities to the same binary outcome. The most cautious target ($12) still reflects substantial upside from current levels, while the highest target ($18) assumes a favorable readout and successful advancement. Analysts have overwhelmingly maintained Buy ratings, but there is no meaningful "consensus" beyond broad optimism about the pipeline. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
As of the latest verified close, shares of COYA traded near $2.95, well below a 52-week range of roughly $2.72 to $6.62. Reaching a $15 price target would require an advance of approximately 400%, which is a very large move by any standard and typical of early-stage biotech, where value is concentrated in future clinical catalysts rather than current financials.
The path hinges almost entirely on the COYA 302 program for ALS. The ALSTARS Phase 2/3 trial completed enrollment with 137 participants, and the company expects topline data from the 24-week double-blind phase in early Q2 2027, with FTD biomarker data expected in Q1 2027. Coya ended Q3 2026 with about $35.8 million in cash, which management indicated should fund operations into the second half of 2027, past the ALSTARS readout. Revenue remains minimal and derived from a collaboration, not product sales.
Shares of COYA have traded in a wide range between about $2.72 and $6.62 over the past year. The current price near the lower end of that band leaves limited obvious technical support below before multi-year lows, while any recovery would first need to reclaim the psychological $5 level and then the mid-$6 zone before the $12 target even enters view. Resistance in the single digits is largely defined by prior breakdown levels rather than durable demand zones, underscoring how much of the eventual move would depend on fundamental news flow.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms set their own assumptions, and biotech targets are unusually sensitive to single catalysts. The key events to watch are the FTD biomarker data expected in Q1 2027, the ALSTARS topline readout in early Q2 2027, any financing announcements, and analyst target revisions around those milestones. Quarterly cash-burn updates and regulatory interactions will also shape the risk-reward profile. From what I see, these catalysts will be the decisive inputs.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like COYA, such tools can help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual review alone. Consider exploring these signals to complement your own research.
In my own work following names like this, I regularly use Tickeron’s AI Daily Buy/Sell Signals to cross-check sentiment shifts and technical setups around upcoming catalysts. The platform’s AI-driven approach helps surface patterns across thousands of securities without requiring hours of manual screening, which is especially useful for binary-event biotech stocks where timing around data readouts can matter a great deal. It has become a practical part of how I stay organized on volatile opportunities.
The $15 central target for Coya Therapeutics represents the arithmetic mean of six analyst targets ranging from $12 to $18, and it sits roughly 400% above the latest price near $2.95 — a very large move that can only be justified by clinical success. The strongest supports are a fully enrolled pivotal ALS trial and a near-term catalyst calendar, while the principal obstacles are binary clinical risk, widening losses, and financing needs. Analysts broadly remain constructive, but their wide target range reflects genuine disagreement about the odds. Investors should monitor the FTD and ALSTARS data readouts and any capital-raising activity as the decisive inputs to whether the target becomes attainable. I’m watching this closely as the data milestones approach.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Indicator for COYA moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 25 of the 27 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 48 cases where COYA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for COYA just turned positive on November 16, 2026. Looking at past instances where COYA's MACD turned positive, the stock continued to rise in 35 of 38 cases over the following month. The odds of a continued upward trend are 90%.
Following a +3.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where COYA advanced for three days, in 168 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
COYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on COYA as a result. In 68 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The 50-day moving average for COYA moved below the 200-day moving average on October 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for COYA entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.621) is normal, around the industry mean (3.596). P/E Ratio (-2.794) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (11.062) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. COYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology